Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If approved, ...
April 21, 2026 expert reaction sequential safety surveillance of RSVpreF vaccination during pregnancy early in the post approval period . A surveillance study published in JAMA Ne ...
The oncolytic virus immunotherapy market presents opportunities with three approved therapies, extensive clinical trial pipelines, and innovative research by biotechnology and pharmaceutical companies ...
Rising cases in the U.S. and globally highlight gaps in vaccination coverage and growing vulnerabilities in public health ...
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
A UW-Madison scientist allegedly admitted to poisoning a colleague's water bottle with toxic chemicals after feeling slighted ...
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...
We are giving away a pair of tix + parking & Club Alta Access to May 9th game vs OCSC at Lancaster Municipal Stadium ...
Younger non-smokers who ate diets rich in fruits, vegetables and whole grains showed a surprising link to lung cancer, early ...
Opinion: Even now, Trump's defenders won't be honest.
April 2026 at 7.30 EETSummary of the quarterReturn on equity 15.4% ? earnings per share EUR 0.36. Nordea's return on equity for the quarter was 15.4%, compared with 15.7% a year ago, reflecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results